By Andrew Silver SHANGHAI (Reuters) -German healthcare and materials group Merck KGaA has dropped a surcharge on life ...

Germany's Merck KGaA said on Thursday it is in late-stage talks to acquire U.S.-based SpringWorks Therapeutics for about $3.5 billion, a deal that could give it access to a recently approved rare ...

German drug company Merck KGaA said Monday it has struck a deal to buy U.S. biotech firm SpringWorks Therapeutics for around $3.9 billion, expanding its portfolio of rare disease and cancer treatments ...

Despite Merck KGaA’s lupus drug failing to prove itself against one form of the autoimmune disease, the German drugmaker has ...

Trump has claimed the move could cut US drug prices by 30 to 80 percent. However, according to German consultancy ...

Germany’s Merck KGaA agreed to acquire U.S. biopharmaceutical company SpringWorks Therapeutics for around $3.9 billion, in a bid to expand its oncology and rare disease business. The German life ...

Merck KGaA, the German science and technology group, trimmed its profit forecast, citing a weakening US dollar and ...

As per media reports in February, Merck Germany reacted to press reports and confirmed advanced discussions with SpringWorks Therapeutics. The offer represents a 26% premium over SpringWorks' 20 ...

Shares fell after the company cut its full-year guidance on the back of challenging macroeconomic conditions and ...

(Reuters) - Germany's Merck KGaA said on Thursday it is in late-stage talks to acquire U.S.-based SpringWorks Therapeutics for about $3.5 billion, a deal that could give it access to a recently ...